The Latest Breaking News from Vinay Prasad

On Monday, Replimune Group Inc. (NASDAQ:REPL) is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage.

Loomer's purge machine.

Loomer's latest victory.

Vinay Prasad resigns from the FDA after backlash over vaccine restrictions and gene therapy decisions. Political pressure cited in sudden departure.

In May, FDA Commissioner Marty Makary named Vinay Prasad the next director of the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER). Within three months, Prasad resigned.

Trump administration gives no details about reason for departure of Vinay Prasad, but he had critics and had taken unusual actions

The Food and Drug Administration named a longtime pharmaceutical executive to run the agency’s drug program

Amid Trump cuts and state-level backlash, experts worry that progress in messenger RNA vaccines could stall

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines

Frustration and anger mount as Trump administration contemplates new trials and restrictions for Covid vaccines